You are here

SARC004

Completed
Study of a short course of neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans
Type of Sarcoma: 
Dermatofirbrosarcoma Protuberans
Drug: 
Gleevec (Imatinib Mesylate)
Accrual Status: 
Closed
Overall Study Principal Investigator: 

Scott Schuetze, MD, PhD
University of Michigan

For more information about this trial and open sites: